Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
about
Glucagon and heart in type 2 diabetes: new perspectivesAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaNiclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetesDegradation and Stabilization of Peptide Hormones in Human Blood SpecimensMajor urinary protein regulation of chemical communication and nutrient metabolismInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?N-glycan remodeling on glucagon receptor is an effector of nutrient sensing by the hexosamine biosynthesis pathwayInsulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humansComputational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus.Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes MellitusMinireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.Hepatic TRAF2 regulates glucose metabolism through enhancing glucagon responses.Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity.Menin liver-specific hemizygous mice challenged with high fat diet show increased weight gain and markers of metabolic impairment.Activation of enteroendocrine membrane progesterone receptors promotes incretin secretion and improves glucose tolerance in miceCoadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemiaCurrent insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.A review of exenatide as adjunctive therapy in patients with type 2 diabetes.Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.Gut-liver interaction in triglyceride-rich lipoprotein metabolism.The role of dysregulated glucagon secretion in type 2 diabetes.Structural aspects of gut peptides with therapeutic potential for type 2 diabetes.Islet α cells and glucagon--critical regulators of energy homeostasis.Inhibiting or antagonizing glucagon: making progress in diabetes care.The New Biology and Pharmacology of Glucagon.Per-arnt-sim (PAS) domain kinase (PASK) as a regulator of glucagon secretion.Glucagon receptor inactivation leads to α-cell hyperplasia in zebrafish.Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy.Glucagon-producing cells are increased in Mas-deficient mice.Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction.Glucagon as a critical factor in the pathology of diabetesGlucagon's effect on liver protein metabolism in vivo.Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
P2860
Q26738580-287C7EFE-E4B6-4B45-B304-2DA09E03D099Q26830274-ED97395A-B671-45EA-9AF8-854F0C0167C4Q27027920-850F1571-655B-4C47-A924-883CB4A4B006Q28085593-53EBC5E8-1021-451A-B00A-2FCFEADA2632Q28359714-AF54E717-B173-421E-999B-BC7E76D34736Q28546842-2BBCACB9-85BD-4076-B176-4911EE7A8D0CQ30156037-A416F07D-50E9-46A6-AAA8-DA7A7D748A06Q30426407-0B8FB33E-0492-413F-97E3-5A990A4ED07DQ33718411-8FCC5806-DCFA-44F9-ADE4-D064F8828292Q33865096-783AF626-8C5F-422A-A6AF-04D7D6909A6FQ33997146-0C2D0E65-15BC-42F3-BC11-02784E0E27D7Q34526962-2A6C9B48-1C54-421F-9D89-6E4BD770305FQ34913473-6B2A2964-DF92-460E-BE24-686BAE3A3E65Q35062439-E940B647-B058-44B2-9BE6-501EE30073BBQ35762651-1182039F-29B5-4B59-8289-D3F56EE25E7AQ35766938-E6E9E884-0812-477F-8ED9-BA66064D4CEFQ35971449-881D3326-4C07-4184-954F-AC5A0E2959A5Q36004187-BFE1F4EE-BDAE-4EB2-8240-D4EF65F83B33Q36477333-9D7E5A64-0880-49B0-82D4-7935B69A5723Q36720596-ADA7AEF2-3FDF-4316-9E22-FDC7E78FC8F5Q37260041-49888D9C-D7B0-44BB-B887-2500D5BEF776Q37403218-46A5A599-13F8-48F0-BF30-512DCA34409CQ37561118-30BAAFCD-BDD6-4700-92C8-0A270ACEC6E1Q37892758-7E4B0388-4E35-46D0-BB44-0404EBA52AE8Q37913523-2A1FEF62-D654-4F0E-AEDC-E68145346746Q38071991-54F041C1-A963-4E4C-813F-48D9A1C9FE1AQ38409880-862E10EF-1AA5-4A9C-8B9D-50506EBFB09DQ38449296-804CF8B8-D2E4-432A-87E4-14CF81392AA0Q38919742-B0CE0EFC-2E30-4689-B78D-6BB7FE5F0201Q39590710-4D099520-C8B9-4AFC-8D0E-16E77C1F6213Q41085982-3493EECE-2FB5-4652-9443-DE4BD200F592Q41847888-A4D3BED3-EE59-4950-A9C7-0DEC53E95B64Q42009046-0F6B158A-CE3E-4AF0-A0A0-DC014AA0D3A2Q42136958-EE77D18E-9D6A-475C-9155-2BDF5903DEF8Q42170069-25D226F7-F7AA-4C51-B30A-503F393E3949Q42273026-0E002DE6-1F31-4704-99AD-E0D1BBE13E8EQ42510088-40F6E990-E474-4E37-BC16-86348EBE5920Q47566343-77C90195-BEAF-4205-8B12-90455A245ADEQ47625288-0033AFE5-3B32-496F-881C-397829F8553FQ47875169-6B3B5C7A-E692-4C93-A5D7-861054420DC6
P2860
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefits and limitations of re ...... treatment of type 2 diabetes.
@en
Benefits and limitations of re ...... treatment of type 2 diabetes.
@nl
type
label
Benefits and limitations of re ...... treatment of type 2 diabetes.
@en
Benefits and limitations of re ...... treatment of type 2 diabetes.
@nl
prefLabel
Benefits and limitations of re ...... treatment of type 2 diabetes.
@en
Benefits and limitations of re ...... treatment of type 2 diabetes.
@nl
P2860
P1476
Benefits and limitations of re ...... treatment of type 2 diabetes.
@en
P2093
Safina Ali
P2860
P304
P356
10.1152/AJPENDO.90887.2008
P577
2008-12-30T00:00:00Z